By Topic

Exploiting the cancer and diabetes metabolic connection for therapeutic purposes

Sign In

Cookies must be enabled to login.After enabling cookies , please use refresh or reload or ctrl+f5 on the browser for the login options.

Formats Non-Member Member
$33 $13
Learn how you can qualify for the best price for this item!
Become an IEEE Member or Subscribe to
IEEE Xplore for exclusive pricing!
close button

puzzle piece

IEEE membership options for an individual and IEEE Xplore subscriptions for an organization offer the most affordable access to essential journal articles, conference papers, standards, eBooks, and eLearning courses.

Learn more about:

IEEE membership

IEEE Xplore subscriptions

4 Author(s)
Osama A. Arshad ; Dept. of Electr. & Comput. Eng., Texas A&M Univ., College Station, TX, USA ; Priyadharshini S. Venkatasubramami ; Aniruddha Datta ; Jijayanagaram Venkatraj

The uncontrolled cell proliferation that is characteristically associated with cancer is usually accompanied by alterations in the genome and cell metabolism. Indeed, the phenomenon of cancer cells metabolizing glucose using a less efficient anaerobic process even in the presence of normal oxygen levels, termed the Warburg effect, is currently considered to be one of the hallmarks of cancer. Diabetes, much like cancer, is defined by significant metabolic changes. Recent epidemiological studies have shown that diabetes patients treated with the anti-diabetic drug Metformin, have significantly lowered risk of cancer as compared to patients treated with other anti-diabetic drugs. We utilize a Boolean logic model of the pathways commonly mutated in cancer to not only investigate the efficacy of Metformin for cancer therapeutic purposes but also demonstrate how Metformin in concert with standard therapeutic drugs could provide better and less toxic clinical outcomes as compared to using chemotherapy alone.

Published in:

2013 IEEE International Workshop on Genomic Signal Processing and Statistics

Date of Conference:

17-19 Nov. 2013